Navigation Links
One Gene May Be Key to Myeloma
Date:6/23/2008

The discovery holds promise as a treatment target for this diverse disease, experts say

MONDAY, June 23 (HealthDay News) -- Cancerous myeloma cells are so "addicted" to a gene known as IRF4, they simply can't live without it, new research has revealed.

Reducing the activity of the gene by only 50 percent is enough to kill myeloma cells without compromising other healthy activities, said scientists reporting in the current issue of Nature.

"This pathway is so critical to the growth of myeloma that, potentially, if you turn it off, you've found a chink in the armor," said Dr. Bart Kamen, executive vice president and chief medical officer at The Leukemia & Lymphoma Society.

The gene could present a target for future drug development.

"IRF4 is absolutely a target in myeloma. This is not an easy target but not an impossible target," said Dr. Louis Staudt, senior author of the paper and chief of the Lymphoid Malignancies Section, Metabolism Branch, Center for Cancer Research at the U.S. National Cancer Institute.

"It's obviously a little bit away, but we have the ability to fairly quickly figure out how to block [genes]," added Dr. Mitchell Smith, head of the lymphoma service at Fox Chase Cancer Center in Philadelphia.

Multiple myeloma, a cancer of the white blood cells, primarily affects older adults and, partly for that reason, often doesn't have a good prognosis.

What's more, there are least seven different "flavors" of multiple myeloma, each having its own unique genetic abnormalities, Staudt said. "One worries that would mean we'd need different drugs for each of these."

While there has been an explosion in new drugs to treat the disease over the past five to 10 years, there is still no cure, Smith said.

The authors took advantage of a genetic screen devised several years ago. This "Achilles' heel screen" uses RNA interference to spot particularly vulnerable parts of cancer cells

"It allows you to inactivate one gene at a time in a cancer cell and then ask what happens," Staudt explained. "We looked simultaneously at thousands of different genes . . . and then asked which one prevents the proliferation and survival of cancer cells."

In this study, the screen identified one gene, IRF4, which surfaced no matter what type of multiple myeloma the investigators looked at.

"Basically, every type of myeloma cell for which we have in vitro models is completely dependent on IRF4, such that, when we inhibit it, they die a swift death within a few days in the lab," Staudt said. "This is better than we hoped."

Interestingly, however, the gene is not mutated when cancer is present. "In the vast majority of cases, there was absolutely nothing different between the IRF4 gene in cancer cells compared to any normal cells," Staudt said. "They were completely normal, yet the cells were totally dependent."

Of course, this begged the question, why?

IRF4 turns out to be a transcription factor, meaning it regulates gene expression -- how a gene produces proteins. In this case, IRF4 regulated the expression of about 35 other genes, including MYC, a well-known cancer-causing gene.

"We found that this IRF4 transcription factor was turning on MYC, which itself is a transcription factor that was turning on IRF4. So, you can see that this is a vicious cycle," Staudt explained. "They cycle out of control, and so this is at least part of how it works."

IRF4 is in charge of so many processes, in fact, that the study authors described knocking it out as "death by a thousand cuts."

"If IRF4 is a master regulator of the working of a myeloma cell, this would be a great drug," Staudt said. "We want people to sit up and take notice of IRF4, because it would be effective across the board in all types of myeloma."

More information

Visit The Leukemia & Lymphoma Society for more on multiple myeloma.



SOURCES: Louis Staudt, M.D., Ph.D., chief, Lymphoid Malignancies Section, Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, Md.; Bart Kamen, M.D., Ph.D., executive vice president and chief medical officer, The Leukemia & Lymphoma Society; Mitchell Smith, M.D., Ph.D., head of lymphoma service, Fox Chase Cancer Center, Philadelphia; Nature


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Emory researchers identify signaling protein for multiple myeloma
2. Human C-reactive protein regulates myeloma tumor cell growth and survival
3. Gene profiling can single out the worst cases of multiple myeloma and guide therapy
4. Gene Test Could Boost Myeloma Treatment
5. The Leukemia & Lymphoma Society Provides Patients with the Latest Information on Myeloma
6. Thalidomide Improves Outcomes for Older Myeloma Patients
7. FDA Expands VELCADE(R) (Bortezomib) for Injection Label for Patients with Multiple Myeloma
8. Studies attribute recent increase in multiple myeloma survival to novel therapies
9. Drug Combo Boosts Multiple Myeloma Survival
10. Penns Abramson Cancer Center part of major phase III study for myeloma
11. Drug combination effective against multiple myeloma, researchers show
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
One Gene May Be Key to Myeloma
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding ... of its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. ... James M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from PsychTests.com reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. Her son ... lash out at his family verbally and physically. , “When something upset him, he couldn’t ... would use it. He would throw rocks at my other children and say he was ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... According to a new market ... Needles, Safety Pen Needles), Needle Length (4mm, 5mm, 6mm, ... of Purchase (Retail, Non-Retail) - Trends & Global Forecasts ... market for the forecast period of 2016 to 2021. ... by 2021 from USD 1.65 Billion in 2016, growing ...
(Date:6/23/2016)... , June 23, 2016 Research ... Devices Global Market - Forecast to 2022" report to ... the treatment method for the patients with kidney failure, it ... excess fluid from the patient,s blood and thus the treatment ... potassium and chloride in balance. Increasing number ...
(Date:6/23/2016)... -- Research and Markets has announced the addition ... - Forecast to 2022" report to their offering. ... to date financial data derived from varied research sources to ... potential impact on the market during the next five years, ... of sub markets, regional and country level analysis. The report ...
Breaking Medicine Technology: